Vor Biopharma Inc.

NasdaqGS:VOR Stock Report

Market Cap: US$54.3m

Vor Biopharma Management

Management criteria checks 3/4

Vor Biopharma's CEO is Robert Ang, appointed in Aug 2019, has a tenure of 5.25 years. total yearly compensation is $2.69M, comprised of 22.5% salary and 77.5% bonuses, including company stock and options. directly owns 0.86% of the company’s shares, worth $468.62K. The average tenure of the management team and the board of directors is 2.1 years and 4.3 years respectively.

Key information

Robert Ang

Chief executive officer

US$2.7m

Total compensation

CEO salary percentage22.5%
CEO tenure5.3yrs
CEO ownership0.9%
Management average tenure2.1yrs
Board average tenure4.3yrs

Recent management updates

Recent updates

Vor Biopharma (NASDAQ:VOR) Will Have To Spend Its Cash Wisely

Sep 10
Vor Biopharma (NASDAQ:VOR) Will Have To Spend Its Cash Wisely

We're A Little Worried About Vor Biopharma's (NASDAQ:VOR) Cash Burn Rate

May 24
We're A Little Worried About Vor Biopharma's (NASDAQ:VOR) Cash Burn Rate

Here's Why We're Watching Vor Biopharma's (NASDAQ:VOR) Cash Burn Situation

Dec 05
Here's Why We're Watching Vor Biopharma's (NASDAQ:VOR) Cash Burn Situation

Will Vor Biopharma (NASDAQ:VOR) Spend Its Cash Wisely?

Aug 18
Will Vor Biopharma (NASDAQ:VOR) Spend Its Cash Wisely?

Vor Biopharma (NASDAQ:VOR) Is In A Good Position To Deliver On Growth Plans

May 05
Vor Biopharma (NASDAQ:VOR) Is In A Good Position To Deliver On Growth Plans

Is Vor Biopharma Inc. (NASDAQ:VOR) Trading At A 49% Discount?

Mar 13
Is Vor Biopharma Inc. (NASDAQ:VOR) Trading At A 49% Discount?

We Think Vor Biopharma (NASDAQ:VOR) Needs To Drive Business Growth Carefully

Oct 19
We Think Vor Biopharma (NASDAQ:VOR) Needs To Drive Business Growth Carefully

Vor Bio appoints Eyal C. Attar as chief medical officer

Oct 12

Is Vor Biopharma (NASDAQ:VOR) In A Good Position To Invest In Growth?

Jun 18
Is Vor Biopharma (NASDAQ:VOR) In A Good Position To Invest In Growth?

Vor Biopharma (NASDAQ:VOR) Is In A Good Position To Deliver On Growth Plans

Mar 05
Vor Biopharma (NASDAQ:VOR) Is In A Good Position To Deliver On Growth Plans

Vor Biopharma (NASDAQ:VOR) Is In A Good Position To Deliver On Growth Plans

Aug 30
Vor Biopharma (NASDAQ:VOR) Is In A Good Position To Deliver On Growth Plans

Vor Biopharma: Targeted Therapies For Transplants

Jun 30

We're Not Very Worried About Vor Biopharma's (NASDAQ:VOR) Cash Burn Rate

May 10
We're Not Very Worried About Vor Biopharma's (NASDAQ:VOR) Cash Burn Rate

Vor Biopharma EPS misses by $0.03

May 06

CEO Compensation Analysis

How has Robert Ang's remuneration changed compared to Vor Biopharma's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2024n/an/a

-US$112m

Jun 30 2024n/an/a

-US$118m

Mar 31 2024n/an/a

-US$120m

Dec 31 2023US$3mUS$606k

-US$118m

Sep 30 2023n/an/a

-US$116m

Jun 30 2023n/an/a

-US$106m

Mar 31 2023n/an/a

-US$98m

Dec 31 2022US$5mUS$570k

-US$92m

Sep 30 2022n/an/a

-US$86m

Jun 30 2022n/an/a

-US$81m

Mar 31 2022n/an/a

-US$78m

Dec 31 2021US$2mUS$508k

-US$70m

Sep 30 2021n/an/a

-US$70m

Jun 30 2021n/an/a

-US$65m

Mar 31 2021n/an/a

-US$56m

Dec 31 2020US$3mUS$424k

-US$49m

Compensation vs Market: Robert's total compensation ($USD2.69M) is above average for companies of similar size in the US market ($USD650.80K).

Compensation vs Earnings: Robert's compensation has been consistent with company performance over the past year.

CEO

Robert Ang (49 yo)

5.3yrs

Tenure

US$2,691,044

Compensation

Dr. Robert Ang, MBBS, MBA, M.D., serves as Independent Non-Executive Director at Enara Bio Limited since September 2021 and serves as its Chairman since August 2024. He is the President, Chief Executive Of...

Leadership Team

NamePositionTenureCompensationOwnership
Robert Ang
President5.3yrsUS$2.69m0.86%
$ 468.6k
Tirtha Chakraborty
Chief Scientific Officer4yrsUS$1.31m0.14%
$ 78.5k
Eyal Attar
Chief Medical Officer2.1yrsUS$1.40m0.015%
$ 8.2k
Siddhartha Mukherjee
Scientific Founder & Chairman of Scientific Advisory Boardno datano datano data
Han Choi
Chief Financial Officerless than a yearno datano data
Amy Quinlan
Interim Principal Accounting Officerless than a yearno data0.042%
$ 22.7k
Tania Philipp
Chief People Officer4.9yrsno datano data
John King
Chief Commercial Officer & Head of Business Development4.3yrsno datano data
Samir Vattompadam
Senior Vice President of Portfolio Strategy & Program Management1.1yrsno datano data
David Phillips
Senior VP & Head of Quality1.1yrsno datano data

2.1yrs

Average Tenure

51yo

Average Age

Experienced Management: VOR's management team is considered experienced (2.1 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Robert Ang
President5.3yrsUS$2.69m0.86%
$ 468.6k
Siddhartha Mukherjee
Scientific Founder & Chairman of Scientific Advisory Boardno datano datano data
David Lubner
Independent Director4.3yrsUS$151.60k0%
$ 0
Matthew Patterson
Independent Chairman of the Board4.1yrsUS$185.60k0.0088%
$ 4.8k
Joshua Resnick
Independent Director5.8yrsUS$157.50k0%
$ 0
Eric Sievers
Scientific & Clinical Advisorno datano datano data
Sven Lundberg
Independent Director5.7yrsUS$152.10k0.043%
$ 23.3k
Daniella Beckman
Independent Director4.3yrsUS$164.10kno data
Steven Devine
Scientific & Clinical Advisorno datano datano data
Robert Soiffer
Scientific & Clinical Advisorno datano datano data
Hans-Peter Kiem
Scientific & Clinical Advisorno datano datano data
Soheil Meshinchi
Scientific & Clinical Advisor3.8yrsno datano data

4.3yrs

Average Tenure

53yo

Average Age

Experienced Board: VOR's board of directors are considered experienced (4.3 years average tenure).